Digoxin

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Digoxin

Examples of brand names: Lanicor [DE]

ATC code: C01AA05

Main use (for orientation): Heart failure; heart-rate control

Documented research summary

No human CBD/THC–digoxin interaction evidence identified. CBC/CBCA showed no inhibition of the investigated ABC transport activity in an in-vitro transport model (Etchart 2022); not clinical safety evidence. A human experiment with synthetic CB1 inverse agonist taranabant (n=12; 6 mg daily, digoxin 0.5 mg) gave an AUC ratio of 0.91 (90% CI 0.83–0.99), Cmax 1.23 (1.09–1.40); not transferable to plant cannabinoids. Knockout-mouse THC and digoxin pharmacokinetics establish transporter function, not a co-medication interaction.

Uncertainties and limitations

The Etchart abstract apparently reverses transporter-substrate assignments; an indexed original methods excerpt names digoxin for ABCB1 and prazosin for ABCG2. No probe-specific figure was therefore extracted; full text inaccessible (403). CBC/CBCA null finding only in vitro.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

CBC/CBCA – laboratory and animal studies

Finding ID: B0167

Type of result: Preclinical null/contrary finding

Observation: CBC and CBCA did not inhibit ABCB1-mediated digoxin transport in the MDCK assay assessed.

Mechanism: In-vitro transporter assessment

Study type: MDCK Transwell transport assay

Context studied: Etchart 2022; digoxin as an ABCB1 transport probe in MDCK cells, not patients.

Clinical interpretation: No clinical safety conclusion possible

Limitations and uncertainties: Original results snippet assigns digoxin to ABCB1 and prazosin to ABCG2; original conclusion confirms the negative ABCB1–digoxin finding. The abstract reverses the assignment. No quantitative effect size, complete methods or clinical safety assessed; full-text access returned 403.

Original sources for this finding: In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters. [CA_P_35306000]

References and access status

[CA_L_D0203] Digoxin – Human-SPL (D0203_Human_label.json)

Original source / bibliographic reference

Authors: Amneal Pharmaceuticals of New York LLC

Year: 2026

Source type: Official human-use SPL / DailyMed

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CA_P_35306000] In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters.

Original source / bibliographic reference

Authors: Etchart MG, Anderson LL, Ametovski A, Jones PM, George AM, Banister SD, Arnold JC.

Year: 2022

Source type: Preclinical original study: MDCK Transwell transport assays and in-silico docking

DOI: 10.1016/j.ejphar.2022.174836

PMID: 35306000

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility